Contact this trialFirst, we need to learn more about you.
IDH1 Inhibitor
Ivosidenib for Bile Duct Cancer
Recruiting2 awardsPhase 3
Calgary
This trial is testing if ivosidenib is safe and effective for adult patients with advanced liver cancer. Patients will take ivosidenib tablets once a day for 28-day cycles for as long
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service